AZD7268 Safety and Tolerability Study
Public ClinicalTrials.gov record NCT01020799. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multi-center, Randomized, Double-bind, Double-dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of AZD7268 in Patients With Major Depressive Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
Study identification
- NCT ID
- NCT01020799
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 247 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2009 (Type not available)
- Primary completion
- Apr 2010 (Actual)
- Completion
- Apr 2010 (Actual)
- Last update posted
- Apr 17, 2012
2009 – 2010
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | — | — |
| Research Site | Garden Grove | California | — | — |
| Research Site | San Diego | California | — | — |
| Research Site | New Haven | Connecticut | — | — |
| Research Site | Bradenton | Florida | — | — |
| Research Site | Jacksonville | Florida | — | — |
| Research Site | Atlanta | Georgia | — | — |
| Research Site | Rockville | Maryland | — | — |
| Research Site | Cedarhurst | New York | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Rochester | New York | — | — |
| Research Site | Dayton | Ohio | — | — |
| Research Site | Portland | Oregon | — | — |
| Research Site | Memphis | Tennessee | — | — |
| Research Site | Friendswood | Texas | — | — |
| Research Site | Bellevue | Washington | — | — |
| Research Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01020799, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 17, 2012 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01020799 live on ClinicalTrials.gov.